Search Results for: Pharma: Clinical Roundup
-
Facebook-Backing Venture Fund Dips a $10M Toe into Biotech
Stamford, Conn.-based Purdue Pharma LP's extended-release hydromorphone product Palladone was voluntarily removed from the market in July 2005 less than a year after approval because of a high occurrence of unintentional "dose-dumping" – when opioids are accidentally or intentionally crushed or dissolved, resulting in the active ingredient being rapidly released into the bloodstream, often causing a euphoric high...is an immediate-release version, which is sold by Purdue Pharma as Dilaudid...NetBy Catherine Shaffer | BioWorld Today | Tuesday, December 27, 2011 -
Clinic Roundup
Radius Health Inc., of Cambridge, Mass., reported that its transdermal BA058 microneedle patch, for osteoporosis, showed positive results in a Phase Ib clinical study...UCB Pharma SA, of Brussels, Belgium, began a trial (EXXELERATE) of Cimzia (certolizumab pegol) plus methotrexate compared with Humira (adalimumab) plus methotrexate for rheumatoid arthritisBioWorld Today | Thursday, December 22, 2011 -
Orexigen Adding $90M Publicly, Ready for Contrave CVOT Trial
Cerulean Pharma Inc., of Cambridge, Mass., closed a $15 million Series D financing with participation from new investor CVF LLC, an affiliate of Henry Crown and Co., of Chicago, and full participation from existing investors Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital and Bessemer Venture Partners...Cerulean also plans to advance its docetaxel nanopharmaceutical candidate into clinical trials and to pursue other platform expansion opportunities, including the delivery of RNABy Jennifer Boggs | BioWorld Today | Friday, December 16, 2011 -
YM Reports Phase I/II Success In Myelofibrosis; Shares Rise
It's a great fit with clinical need and best suited to deal with the three major factors associated with myelofibrosis...Alnylam Pharmaceuticals Inc., of Cambridge, Mass., reported clinical data from a number of programs...Astellas Pharma Inc., of Tokyo, and Ambit Biosciences Corp., of San Diego, shared updated results from an interim analysis of a Phase II trial of quizartinib (previously AC220) in acute myeloid leukemia, showing that quizartinib monotherapy had activity in refractory and relapsedBy Catherine Shaffer | BioWorld Today | Wednesday, December 14, 2011 -
ASH Roundup
AMAG Pharmaceuticals Inc., of Lexington, Mass., presented new clinical data for Feraheme (ferumoxytol), which is approved for iron deficiency anemia in chronic kidney disease...Clavis Pharma ASA, of Oslo, Norway, reported interim efficacy data from a Phase II trial showing that elacytarabine in combination with idarubicin produced a complete remission rate in about 46 percent (12 of 26) of patients with early stage acute myeloid leukemia who had failed cytarabine-containing first-courseBioWorld Today | Tuesday, December 13, 2011 -
Clinic Roundup
Metabolex Inc., of Hayward, Calif., said an open-label clinical pharmacology study showed that the higher dose of arhalofenate plus Osaka, Japan-based Takeda Pharmaceutical Co...Tranzyme Pharma Inc., of Research Triangle Park, N.C., and Norgine BV, of Amsterdam, the Netherlands, completed patient enrollment in ULISES 007, the first of two pivotal Phase III studies of ulimorelin, an intravenous ghrelin agonist, for the acceleration of gastrointestinal recovery in patients undergoing partial bowelBioWorld Today | Friday, December 9, 2011 -
Inhibitex Jumps on HCV Data; Raises $20M in ATM Financing
But, if data for INX-189 continue to flow positive, the company could find itself in an enviable position for a lucrative big pharma partnership or even an acquisition, as biopharma races to create the first all-oral, interferon-free HCV regimen...Proceeds will be used to accelerate the firm's drug development pipeline, including generating clinical data from partnerships in Russia and India.By Jennifer Boggs | BioWorld Today | Wednesday, November 30, 2011 -
ChanRx Closes Series A to Advance Atrial Fib Drug
oral vernakalant, which partners Cardiome Pharma Corp., of Vancouver, British Columbia, and Merck & Co...What attracted us was the potential to do a targeted investment to validate an early clinical signal," Graham told BioWorld Today...acting as co-managers.By Marie Powers | BioWorld Today | Wednesday, November 23, 2011 -
AACR Roundup
The compound demonstrated preliminary but encouraging single-agent clinical activity in both indications...Niiki Pharma Inc., of Hoboken, N.J., reported preclinical combination studies showing that its lead product, NKP-1339, demonstrated synergistic activity in both in vitro and in vivo models when given with a broad range of antitumor agents...In vitro studies tested the drug in combination with cisplatin, oxaliplatin, 5-FU, docetaxel, doxorubicin, gemcitabine, Tarceva (erlotinib, Astellas PharmaBioWorld Today | Wednesday, November 16, 2011 -
Another IPO! TVAX Seeks $40M To Fund Cancer Immunotherapy
The company said proceeds from the IPO would see the company through 2013 and allow it to advance the TVI-Brain-1 clinical program, though additional financing would be needed to complete clinical trials of the compound...Affiris is developing peptide vaccines, including a vaccine for Parkinson's disease set to start Phase I testing in early 2012.By Marie Powers | BioWorld Today | Wednesday, November 9, 2011 -
Clinic Roundup
Cardiome Pharma Corp., of Vancouver, British Columbia, said partner Merck & Co...Galena Biopharma Inc., of Lake Oswego, Ore., reported that data from Phase II clinical trials of its NeuVax vaccine showed that it may provide a meaningful clinical benefit in patients with less aggressive forms of breast cancer, and potentially keep them free of their disease...Rexahn said the firm plans to evaluate the Serdaxin clinical programs and possible paths forwardBioWorld Today | Monday, November 7, 2011 -
Clinic Roundup
Ampio Pharmaceuticals Inc., of Greenwood Village, Colo., reported positive results from the Ampion-In-Knee (AIK) clinical trial, showing the drug was well tolerated and reduced pain over and above steroids...The decision follows reports of laboratory abnormalities and adverse events in a subset of clinical trial participants...Solasia Pharma K.K., of Tokyo, reported that enrollment of a Phase I trial evaluating the safety and tolerability of darinaparsin injection (SP-02L) for the treatment ofBioWorld Today | Thursday, October 27, 2011 -
Clinic Roundup
Clavis Pharma ASA, of Oslo, Norway, established the cutoff level for defining hENT1 low vs...Low hENT1 levels have been correlated to poor clinical outcome with gemcitabine, the standard treatment for many solid tumors...PharmaGap Inc., of Ottawa, said it has chosen ovarian cancer as its target for clinical development of GAP-107B8BioWorld Today | Tuesday, October 25, 2011 -
With $42M Series A, Dermira Amasses Dermatology Assets
Add in large target markets and a cost-efficient clinical development path, and you've got a salve for many of the issues currently ailing other sectors of the drug industry...He previously headed Peplin Inc., which garnered positive data in its first pivotal trial of actinic keratosis drug PEP005 and was promptly acquired by LEO Pharma A/S for $287.5 million. (See BioWorld Today, Sept. 4, 2009.) So Wiggans teamed up with scientist Eugene Bauer, who'd had similar experiences...QLT eventually spun-outBy Trista Morrison | BioWorld Today | Monday, October 24, 2011 -
Clinic Roundup
Galderma Pharma SA, of Lausanne, Switzerland, reported top-line results from a Phase IIb trial showing that CD07805/47, a topical gel in development for moderate to severe facial erythema of rosacea, was rapidly effective at reducing facial redness...Data, which resulted from a pooled analysis of five trials in postsurgical pain management, were presented at the American College of Clinical Pharmacy meeting in PittsburghBioWorld Today | Friday, October 21, 2011 -
Cempra Joins IPO Queue; Files for $85.26M Offering
Following a handful of IPO pricings earlier in the year, activity dropped off over the summer, with only one company going public: specialty pharma firm Horizon Pharma Inc...Amarantus is developing products based on MANF, a protein that corrects protein misfolding.By Jennifer Boggs | BioWorld Today | Friday, October 14, 2011 -
Clinic Roundup
Dynavax will manage early clinical development, with AstraZeneca providing approximately $20 million to cover the cost of clinical development activities through Phase IIa...Tranzyme Pharma, of Research Triangle Park, N.C., dosed its first patient in a Phase IIb, 12-week trial of TZP-102, its oral gastrointestinal (GI) motility drug candidateBioWorld Today | Thursday, October 6, 2011 -
Kythera Sitting Pretty with $37M for ATX 101 Phase III
The company has completed seven clinical trials of the minimally invasive procedure, known as adipolytic therapy, enrolling more than 350 patients...The funding will be used for preclinical and clinical development and commercial efforts...The company has candidates in clinical development to treat nephropathic cystinosis, nonalcoholic steatohepatitis, Huntington's disease, aldehyde dehydrogenase deficiency and thrombotic disorderBy Marie Powers | BioWorld Today | Tuesday, September 20, 2011 -
Financings Roundup
Proceeds will be used to fund clinical trial activities relating to progressive supranuclear palsy drug davunetide, as well as for general administrative expenses, working capital and general corporate purposes...Proceeds are expected to help the specialty pharma firm expand its commercialization activities, prepare for the extension of its product line including Altrazeal Collagen and Altrazeal Silver and position it for negotiating with potential partnersBioWorld Today | Friday, September 16, 2011 -
Clinic Roundup
Acceleron Pharma Inc., of Cambridge, Mass., said it started a Phase I study of ACE-536, a ligand trap designed to increase red blood cells and hemoglobin by inhibiting member of the TGF-beta superfamily involved in late stages of erythropoiesis...Under the firms' 2010 deal, Otsuka will contract with Acucela for early clinical development in exchange for an opt-in right to co-develop and co-promote the compound in the U.S...Ascendis Pharma A/S, of Copenhagen, Denmark, said a Phase II study of ACP-001BioWorld Today | Wednesday, September 14, 2011
Category
Current Filters
- xNOT drug application
Related Keywords
Categories
- x BioWorld Today (446)
- x BioWorld International (7)
- x Bio Perspectives (1)
- x State of the Industry Report (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.